Jin-Young Huh

Evaluation of stress patterns generated by reduction forceps within a photoelastic mandibular model.

INTRODUCTION Little attention has been paid to the mechanical effects of fracture reduction forceps. AIM This study aims to evaluate the stress patterns within the fractured mandible generated by reduction forceps. MATERIAL AND METHODS Thirty-six mandibular models were fabricated using a photoelastic resin. Each of the three sets of mandibular models was osteotomized according to one of three different fracture types. After reducing the cut segments, reduction forceps were placed into different engagement holes to compress the segments. Photoelastic stress analysis was used to visualize the stress patterns within the fractured mandibular models as generated by the reduction forceps. RESULTS In the case of symphyseal or parasymphyseal fractures, an optimum distribution of stresses over the fracture site was achieved when placing the reduction forceps more than 12mm away from either side of the fracture line, between the midway level of the mandibular height (bisecting the mandible) and 5mm below this level. In the case of body fractures, optimum stress distribution was achieved when the reduction forceps were placed more than 16mm from the fracture line at the midway level. CONCLUSION Correct use of the reduction forceps helps to provide a precise three-dimensional reduction for mandibular fractures.

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis

REFERENCES 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. 2. Hong J, Lee JH. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med 2016;31:820-34. 3. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009;89:14-23. 4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20. 5. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63:789-99. 6. Ide M, Kuwahara N, Matsuishi E, Kimura S, Gondo H. Uncommon case of chronic myeloid leukemia with multiple myeloma. Int J Hematol 2010;91:699-704. 7. Alsidawi S, Ghose A, Qualtieri J, Radhakrishnan N. A case of multiple myeloma with metachronous chronic myeloid leukemia treated successfully with bortezomib, dexamethasone, and dasatinib. Case Rep Oncol Med 2014;2014:962526. 8. Offiah C, Quinn JP, Thornton P, Murphy PT. Co-existing chronic myeloid leukaemia and multiple myeloma: rapid response to lenalidomide during imatinib treatment. Int J Hematol 2012; 95:451-2. 9. Monroy RH, Vargas-Viveros P, Ceballos EC, Velazquez JC, Munos SC. Imatinib (IM) plus thalidomide (Thali), a effective combination for the treatment of chronic myeloid leukemia (CML) Philadelphia chromosomepositive (Ph +) in IM-resistant disease. Report of 14 new cases from a single center in Mexico. Blood 2013;122:5172. Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis

The Impact of Emergency Adult Living-Donor Liver Transplantation on the Survival of Patients with Antituberculosis Therapy-Induced Acute Liver Failure.

Drug-induced liver injury during treatment for tuberculosis (TB) causes substantial morbidity and may rarely lead to mortality if it progresses to acute liver failure (ALF). The literature regarding the benefits of liver transplantation (LT) for such cases is limited. Therefore, we aimed to investigate this issue in our current study. This study was conducted at a tertiary referral center in South Korea. Between January 2006 and December 2014, 25 patients were diagnosed with ALF while receiving anti-TB treatment. Among these, 19 patients were ultimately included after excluding patients with other possible etiologies. Of these 19 patients, only 3 were diagnosed with TB at our center, whereas the remaining 16 patients were referred for the management of ALF from other hospitals. A total of 10 of the 19 patients were men, and the mean age was 45.9 years. Among the 19 patients, 12 had pulmonary TB and 7 had extrapulmonary TB. Of the 12 patients with pulmonary TB, 8 were cultureconfirmed cases, whereas the remaining 4 patients were diagnosed on the basis of pathologic finding or clinical response to anti-TB medications. Extrapulmonary TB was diagnosed according to previously defined criteria. The mean period of TB treatment before ALF diagnosis was 61.0 days, and the majority of patients received a standard 4-drug anti-TB regimen at the time of ALF diagnosis. The mean Model for End-Stage Liver Disease (MELD) score was 30.1. Eight patients had grade 3-4 encephalopathy. Six patients were not listed for LT because of contraindications to the procedure (advanced age, n5 4; affordability, n5 2). Of the 13 patients listed, 6 received adult living donor liver transplantation (ALDLT). The remaining 7 patients did not receive LT because of the lack of a timely suitable donor. Six patients received emergency ALDLT after a mean of 4.3 days after ALF onset. All patients were alive and in good health at follow-up at a median of 8.2 years (interquartile range, 3.2-8.7 years). After ALDLT, 4 patients completed the course of anti-TB treatment after the regimen was changed to minimally hepatotoxic drugs for a mean of 16.3 months, with successful outcomes. Clinical characteristics of 6 patients are summarized in Table 1. Of the 13 patients who did not receive LT, 10 died of progressive ALF at a median of 15.6 days after ALF onset; 5 (5/6, 83.3%) patients had not been listed for LT and 5 (5/7, 71.4%) patients had been listed but could not undergo LT. Three patients survived following conservative treatment alone; all were in good health at a mean follow-up of 24.5 months. Two Abbreviations: ALDLT, adult living donor liver transplantation; ALF, acute liver failure; AR, acute rejection; CLT, cadaveric liver transplantation; CR, chronic rejection; CS, cycloserine; EMB, ethambutol; HE, isoniazid and ethambutol; HREZ, isoniazid, rifampicin, ethambutol and pyrazinamide; LT, liver transplantation; LVFX, levofloxacin; MELD, Model for End-Stage Liver Disease; PAS, para-aminosalicylate sodium; PTO, prothionamide; SM, streptomycin; TB, tuberculosis.